Faith Davies, MD, discusses the approval of isatuximab-irfc-based combinations for patients with relapsed/refractory multiple myeloma.
Faith Davies, MD, a professor at the Department of Medicine, and the director of the Clinical Myeloma Program at NYU Langone Health’s Perlmutter Cancer Center, discusses the approval of isatuximab-irfc (Sarclisa)-based combinations for patients with relapsed/refractory multiple myeloma.
Two isatuximab-based combinations have been approved by the FDA for the treatment of this patient population, one with pomalidomide (Pomalyst) and dexamethasone, and the other with carfilzomib (Kyprolis) and dexamethasone. These decisions provide options to include either an immunomodulatory drug or a proteasome inhibitor when considering treatment for patients with relapsed/refractory disease, Davies says.
Importantly, data with these combinations have not revealed any unexpected toxicities, and the agent is considered to be well tolerated, according to Davies. There have been reports of infusion reactions, which were well managed, and tended to occur upon administration of the first dose of the agent, Davies says. However, no exasperation of adverse effects have been observed with either combination, Davies concludes.